If the prelim results were brilliant - and they were positive but not exceptional - then why has the SP tumbled?
Great results force the SP up - and this would excite third parties.
Example today:
ASX Health Stocks: INOVIQ pops 45pc after revealing breakthrough exosome therapy to kill breast cancer - *
SP rose 45%.
said it has created specialised exosomes (EEVs) designed to target and destroy breast cancer cells in a lab setting.
In the study, IIQ inserted a cancer targeting protein, chimeric antigen receptor (or CAR), into immune cells, which released the modified/engineered exosomes.
This protein acts like a homing device, guiding the exosomes to the breast cancer cells. Overall, the study found that these engineered exosomes were successful in finding and killing breast cancer cells in their experiments conducted in vitro.
The modified exosomes were isolated and concentrated using INOVIQ’s proprietary EXO-ACE technology, which recovered more than 80% of exosomes with over 95% purity.
In the tests, 75% of breast cancer cells treated with these exosomes experienced cell death within 72 hours.
Encouraged by these promising results, INOVIQ said it plans to further develop its exosome therapeutics program, initially focusing on using immune-cell derived exosomes to treat metastatic breast and ovarian cancers.
Additionally, exosomes can be engineered and loaded with drug cargo, such as RNA therapeutics, to target and deliver effective treatments for neurological diseases across the blood-brain barrier.
CEO Leearne Hinch said INOVIQ has established core capabilities in-house to engineer, load and produce exosomes for therapeutic applications.
“These data highlight the potential of immune-cell derived exosomes as an effective cancer therapy and the potential for RNA drug-loaded exosome therapeutics,” Hinch said.
The company is now moving forward with this program, as it aims to advance towards key preclinical in vitro and in vivo milestones for cancer starting in CY24.
“Preclinical in vivo data are expected to support discussions with pharmaceutical companies for potential partnered exosome therapeutic opportunities,” Hinch added.
INOVIQ’s share price was up +45% this morning.
